Matthew Frohn

Matthew joined the OrganOx board as a Non-Executive Director in 2009, when the company spun-out from the University of Oxford. Matthew has over twenty years of experience as a venture investor, focusing on highly disruptive healthcare, medtech and life science opportunities. In addition to OrganOx, he sits on other boards including Caristo Diagnostics, OxSonics, Momentum BioSciences, BioFidelity and Lightcast Discovery.

Matthew has a D.Phil (Biochemistry) from Oxford. After a brief research career, he began investing in early stage companies through Oxford Technology Management, before co-founding Longwall Venture Partners. Longwall has raised three funds over the last decade, and invests in early stage, UK-based science, engineering and healthcare businesses.